Biomimetic selenium nanomedicine with homologous targeting enhances hepatocellular carcinoma therapy
Materials Today Bio · 2025-12 · 35 · 102441
DOI: 10.1016/j.mtbio.2025.102441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Materials Today Bio, 2025-12. Verfasst von Fang Cui und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, C…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions, Tsinghua Initiative Scientific Research Program.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with limited effective therapeutic options. While trace elements like selenium (Se)-based nanoparticles (SeNPs) show promising anti-tumor effects, their clinical application is greatly hindered by poor targeting efficiency. Here, we engineered a biomimetic Se nanomedicine, CCEVSe, by encapsulating SeNPs within tumor cell-derived extracellular vesicles (CCEVs). Utilizing the inherent homotypic targeting and immune-evasion properties of CCEVs, CCEVSe selectively targets and is effectively internalized by tumor cells of the same origin. In vitro studies confirmed that CCEVSe exhibits superior cytotoxicity by amplifying intracellular reactive oxygen species and inhibiting key malignant behaviors, including proliferation, stemness, and metastasis. In vivo experiments in an HCC xenograft mouse model revealed that CCEVSe achieved superior tumor-specific accumulation, with Se concentrations in tumors approximately four times higher than free SeNPs after one injection. This enhanced targeting led to significant therapeutic efficacy, with CCEVSe achieving up to 87 % tumor growth suppression while exhibiting excellent safety with no observable systemic toxicity. In summary, our study provides a new paradigm for the cell-selective delivery of therapeutic nanomaterials through biomimetic modification, offering a promising strategy for precise HCC therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
- School of Medicine, Hangzhou City University, Hangzhou, 310015, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.
- Department of Medical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102218, China.
- Ningxia University, Yinchuan, 750021, Ningxia, China.
Förderung
- National Natural Science Foundation of China
- EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
- Tsinghua Initiative Scientific Research Program
- Horizon 2020
- Tsinghua University
Zitieren
APA
Cui, F., Huang, Q. X., Yu, Z., Yang, J. J., Liang, S. Y., Wang, M. Q., Zhu, J., Tian, C., Li, S. X., Wang, H. T., Chen, F., Li, Y. J., Feng, X., Liu, R. T., & Zhang, L. (2025). Biomimetic selenium nanomedicine with homologous targeting enhances hepatocellular carcinoma therapy. Materials Today Bio, 35, 102441. https://doi.org/10.1016/j.mtbio.2025.102441
Vancouver
Cui F, Huang QX, Yu Z, Yang JJ, Liang SY, Wang MQ, et al. Biomimetic selenium nanomedicine with homologous targeting enhances hepatocellular carcinoma therapy. Materials Today Bio. 2025;35:102441. doi:10.1016/j.mtbio.2025.102441
BibTeX
@article{Cui2025,
author = {Cui, Fang and Huang, Qi-Xin and Yu, Zhuo and Yang, Jin-Ju and Liang, Shi-Yu and Wang, Mei-Qi and Zhu, Jie and Tian, Chen and Li, Shao-Xun and Wang, Hao-Tian and Chen, Fei and Li, Yang-Jie and Feng, Xiaobin and Liu, Rui-Tian and Zhang, Lingxiao},
title = {Biomimetic selenium nanomedicine with homologous targeting enhances hepatocellular carcinoma therapy},
journal = {Materials Today Bio},
year = {2025},
volume = {35},
pages = {102441},
doi = {10.1016/j.mtbio.2025.102441}
}
EUVIMED